MTOR and colorectal carcinoma: To prove the anti-CRC mechanism of the compounds was related to the PI3K/Akt/mTOR pathway, agonist IGF-1 of PI3K/AKT/mTOR was used for a Western blot assay to test the related effects of the main ingredient 1,3,5,8-tetrahydroxyanthrone (17) in XF and GA (Figure 2).